Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have substantially improved the quality of life and survival of advanced non-small-cell lung cancer (NSCLC) patients [1–5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.